Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption

Journal of Endocrinology

Volumn 229, Issue 1, 2016, Pages 1-12

  Ten Kulve, Jennifer S ^a   Veltman, Dick J ^a   Van Bloemendaal, Liselotte ^a   Groot, Paul F C ^b   Ruhé, Henricus G ^b,c   Barkhof, Frederik ^a   Diamant, Michaela ^a   Ijzerman, Richard G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

fMRI; GLP1; Obesity; Palatable food; Type 2 diabetes

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; PLACEBO; EXENDIN 9; PEPTIDE FRAGMENT;

ADULT; AGED; APPETITE; ARTICLE; BLOOD SAMPLING; CACAO; CAUDATE NUCLEUS; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DIARRHEA; DRUG DOSE INCREASE; FEEDING; FEMALE; FOOD INTAKE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULA; MALE; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; TASTE; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT REDUCTION; BLOOD; CASE CONTROL STUDY; COMPLICATION; EATING; PATHOPHYSIOLOGY; PHYSIOLOGY;

APPETITE; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS, TYPE 2; EATING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LIRAGLUTIDE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBESITY; PEPTIDE FRAGMENTS;

EID: 84973534417     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-15-0461     Document Type: Article

References (54)

1. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Cull JG & Comings DE 1996 The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. Journal of the Royal Society of Medicine 89 396-400.
2. Bunck MC, Corner A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Jarvinen H & Diamant M 2011 Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34 2041-2047. (doi:10.2337/dc11-0291)
3. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M & Blonde L 2009 Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374 39-47. (doi:10.1016/S0140-6736(09)60659-0)
4. Chelikani PK, Haver AC & Reidelberger RD 2005 Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 288 R1695-R1706.
5. Costantini VJ, Vicentini E, Sabbatini FM, Valerio E, Lepore S, Tessari M, Sartori M, Michielin F, Melotto S, Bifone A, et al. 2011 GSK1614343, a novel ghrelin receptor antagonist, produces an unexpected increase of food intake and body weight in rodents and dogs. Neuroendocrinology 94 158-168. (doi:10.1159/000328968)
6. Crawley JN & Beinfeld MC 1983 Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302 703-706.
7. Cummings BP 2013 Leptin therapy in type 2 diabetes. Diabetes, Obesity and Metabolism 15 607-612.
8. Deane AM, Nguyen NQ, Stevens JE, Fraser RJ, Holloway RH, Besanko LK, Burgstad C, Jones KL, Chapman MJ, Rayner CK, et al. 2010 Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. Journal of Clinical Endocrinology and Metabolism 95 215-221. (doi:10.1210/jc.2009-1503)
9. Flint A, Raben A, Astrup A & Holst JJ 1998 Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. Journal of Clinical Investigation 101 515-520.
10. Frank S, Kullmann S & Veit R 2013 Food related processes in the insular cortex. Frontiers in Human Neuroscience 7 499.
11. Garber A, Henry RR, Ratner R, Hale P, Chang CT & Bode B 2011 Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 13 348-356. (doi:10.1111/j.1463-1326.2010.01356.x)
12. Garner DM & Olmsted MP 1986 Scoring the eating disorder inventory. American Journal of Psychiatry 143 680-681.
13. Geary N, Kissileff HR, Pi-Sunyer FX & Hinton V 1992 Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. American Journal of Physiology 262 R975-R980.
14. Hare TA, O'Doherty J, Camerer CF, Schultz W & Rangel A 2008 Dissociating the role of the orbitofrontal cortex and the striatum in the computation of goal values and prediction errors. Journal of Neuroscience 28 5623-5630. (doi:10.1523/JNEUROSCI.1309-08.2008)
15. Heppner KM, Kirigiti M, Secher A, Juel PS, Buckingham R, Pyke C, Knudsen LB, Vrang N & Grove KL 2014 Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 156 255-267. (doi:10.1210/en.2014-1675)
16. Inokuchi A, Oomura Y & Nishimura H 1984 Effect of intracerebroventricularly infused glucagon on feeding behavior. Physiology & Behavior 33 397-400.
17. Kreymann B, Williams G, Ghatei MA & Bloom SR 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2 1300-1304.
18. Levy LM, Henkin RI, Lin CS, Finley A & Schellinger D 1999 Taste memory induces brain activation as revealed by functional MRI. Journal of Computer Assisted Tomography 23 499-505.
19. Merchenthaler I, Lane M & Shughrue P 1999 Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. Journal of Comparative Neurology 403 261-280.
20. Mojsov S, Weir GC & Habener JF 1987 Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. Journal of Clinical Investigation 79 616-619.
21. O'Doherty J, Rolls ET, Francis S, Bowtell R & McGlone F 2001 Representation of pleasant and aversive taste in the human brain. Journal of Neurophysiology 85 1315-1321.
22. Orskov C, Rabenhoj L, Wettergren A, Kofod H & Holst JJ 1994 Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43 535-539. (doi:10.2337/diab.43.4.535)
23. Page KA, Seo D, Belfort-DeAguiar R, Lacadie C, Dzuira J, Naik S, Amarnath S, Constable RT, Sherwin RS & Sinha R 2011 Circulating glucose levels modulate neural control of desire for high-calorie foods in humans. Journal of Clinical Investigation 121 4161-4169. (doi:10.1172/JCI57873)
24. Pelchat ML, Johnson A, Chan R, Valdez J & Ragland JD 2004 Images of desire: food-craving activation during fMRI. NeuroImage 23 1486-1493.
25. Rodriquez de FF, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gomez R, Munoz RM, Eng J & Blazquez E 2000 Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49 709-717.
26. Rothemund Y, Preuschhof C, Bohner G, Bauknecht HC, Klingebiel R, Flor H & Klapp BF 2007 Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals. NeuroImage 37 410-421.
27. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM & Simo R 2009 Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52 2046-2055. (doi:10.1007/s00125-009-1472-y)
28. Schick RR, Zimmermann JP, vorm Walde T & Schusdziarra V 2003 Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 284 R1427-R1435.
29. Schroevers MJ, Sanderman R, van SE & Ranchor AV 2000 The evaluation of the Center for Epidemiologic Studies Depression (CES-D) scale: depressed and positive affect in cancer patients and healthy reference subjects. Quality of Life Research 9 1015-1029.
30. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ & Baskin DG 2000 Central nervous system control of food intake. Nature 404 661-671.
31. Secher A, Jelsing J, Baquero AF, Hecksher-Sorensen J, Cowley MA, Dalboge LS, Hansen G, Grove KL, Pyke C, Raun K, et al. 2014 The arcuate nucleus mediates GLP1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation 124 4473-4488. (doi:10.1172/JCI75276)
32. Shin YK, Martin B, Golden E, Dotson CD, Maudsley S, Kim W, Jang HJ, Mattson MP, Drucker DJ, Egan JM, et al. 2008 Modulation of taste sensitivity by GLP1 signaling. Journal of Neurochemistry 106 455-463.
33. Shugrue PJ, Lane M & Merchenthaler I 1996 Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 137 5159-5162.
34. Sisley S, Gutierrez-Aguilar R, Scott M, D'Alessio DA, Sandoval DA & Seeley RJ 2014 Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. Journal of Clinical Investigation 124 2456-2463. (doi:10.1172/JCI72434)
35. Sloan JH, Siegel RW, Ivanova-Cox YT, Watson DE, Deeg MA & Konrad RJ 2012 A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon. Clinical Biochemistry 45 1640-1644. (doi:10.1016/j.clinbiochem.2012.07.111)
36. Small DM, Zatorre RJ, Dagher A, Evans AC & Jones-Gotman M 2001 Changes in brain activity related to eating chocolate: from pleasure to aversion. Brain 124 1720-1733.
37. Stice E, Spoor S, Bohon C & Small DM 2008a Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science 322 449-452. (doi:10.1126/science.1161550)
38. Stice E, Spoor S, Bohon C, Veldhuizen MG & Small DM 2008b Relation of reward from food intake and anticipated food intake to obesity: a functional magnetic resonance imaging study. Journal of Abnormal Psychology 117 924-935. (doi:10.1037/a0013600)
39. Stoeckel LE, Weller RE, Cook EW III, Twieg DB, Knowlton RC & Cox JE 2008 Widespread reward-system activation in obese women in response to pictures of high-calorie foods. NeuroImage 41 636-647. (doi:10.1016/j.neuroimage.2008.02.031)
40. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH & Egan JM 2000 Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141 1936-1941.
41. Tang DW, Fellows LK, Small DM & Dagher A 2012 Food and drug cues activate similar brain regions: a meta-analysis of functional MRI studies. Physiology & Behavior 106 317-324. (doi:10.1016/j.physbeh.2012.03.009)
42. Ten Kulve JS, Veltman DJ, van Blomendaal L, Barkhof F, Deacon CF, Holst JJ, Konrad RJ, Sloan JH, Drent ML, Diamant M, et al. 2015a Endogenous GLP1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. Diabetologia 58 2688-2698. (doi:10.1007/s00125-015-3754-x)
43. Ten Kulve JS, Veltman DJ, van Blomendaal L, Barkhof F, Drent ML, Diamant M & IJzerman RG 2015b Liraglutide reduces CNS activation in response to visual food cues only after short-term treatment in patients with type 2 diabetes. Diabetes Care 39 214-221. (doi:10.2337/dc15-0772)
44. Trinko R, Sears RM, Guarnieri DJ & DiLeone RJ 2007 Neural mechanisms underlying obesity and drug addiction. Physiology & Behavior 91 499-505.
45. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, et al. 1996 A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 69-72.
46. van Bloemendaal L, IJzerman RG, Ten Kulve JS, Barkhof F, Konrad RJ, Drent ML, Veltman DJ & Diamant M 2014 GLP1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 63 4186-4196. (doi:10.2337/db14-0849)
47. van Bloemendaal L, Veltman DJ, Ten Kulve JS, Groot PF, Ruhe HG, Barkhof F, Sloan JH, Diamant M & IJzerman RG 2015 Brain reward-system activation in response to anticipation and consumption of palatable food is altered by GLP1 receptor activation in humans. Diabetes, Obesity and Metabolism 17 878-886. (doi:10.1111/dom.12506)
48. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ & Astrup A 2001 A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. Journal of Clinical Endocrinology and Metabolism 86 4382-4389.
49. Vilsboll T, Christensen M, Junker AE, Knop FK & Gluud LL 2012 Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344 d7771. (doi:10.1136/bmj.d7771)
50. Volkow ND & Wise RA 2005 How can drug addiction help us understand obesity? Nature Neuroscience 8 555-560.
51. Wang GJ, Volkow ND, Telang F, Jayne M, Ma J, Rao M, Zhu W, Wong CT, Pappas NR, Geliebter A, et al. 2004 Exposure to appetitive food stimuli markedly activates the human brain. NeuroImage 21 1790-1797. (doi:10.1016/j.neuroimage.2003.11.026)
52. Wang GJ, Volkow ND, Thanos PK & Fowler JS 2009 Imaging of brain dopamine pathways: implications for understanding obesity. Journal of Addiction Medicine 3 8-18.
53. Williams DL, Baskin DG & Schwartz MW 2009 Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150 1680-1687.
54. Zald DH & Pardo JV 2000 Cortical activation induced by intraoral stimulation with water in humans. Chemical Senses 25 267-275.